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Conclusions
1. The diabetic retinopathy development is linked to a 
prolonged VEP latency period (P100), lowering the N75-P100 
amplitude, as well as to shortening the recovery period of 
retina’s functional capacity after photo stress.
2. The cerebellar trans-cranial magnetic stimulation fa-
cilitates a faster recovery of the retina’s functional capacity in 
response to photo stress in diabetic patients with retinopathy.
3. The periodical cerebellar trans-cranial stimulations may 
be considered as a prevention method as well as a method of 
treatment of diabetic retinopathy.
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Introduction
The first solid phase of radioimmunoassay was reported 
by K.Catt and G.Treagear in the Science Journal at the earlier 
stage of prostate specific antigen (PSA) development [2].  An 
important aspect of the immune response is the production of 
antibodies or immunoglobulins by B-cells (B-lymphocytes). 
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Abstract
Background: Immunoassay is an appropriate method for measuring hormones and other protein compounds like a prostate-specific antigen (PSA). 
This antigen is a tumor marker of prostate cancer which can be identified by screening.  Among the numerous available solid phases a coated tube is 
the most popular one.
Material and methods: We have used a monoclonal antibody (mAb) against the PSA.  One of the pairs of monoclonal antibodies has been used for 
preparing the PSA tracer by labeling to radioactive iodine (125I) and the other one – for the coating of polystyrene tubes.  In the solid phase method we 
have used the adsorption technique for coating the monoclonal antibody in polystyrene tubes.  We have used adsorption as a mode of coating and plastic 
tubes as a solid phase.  The reaction takes place between the antigen molecule in the patient serum and the two antibodies (anti-PSA mAb) in the tracer 
and coated tubes, and hence these assays are called solid phase assays.  The determination of PSA is based on the immunoradiometric assay (IRMA). 
The samples or standards are incubated in monoclonal antibody-coated tubes with the second 125I-labelled antibody.  After the incubation period (two 
hours) the liquid contents of the tubes are aspirated and washed.
Results: After running the assay the results have showed a correlation between the concentrations of the serum PSA tested by the locally made coated 
tubes and the commercial ones.  So, we can use the locally made reagents to measure the PSA not only for the laboratories performing a large number 
of tests, but also for the whole country in screening  the prostate cancer which will surely be a cost-effective project.  Finally, as the method is isotopic, it 
is more robust compared to the non-isotopic markers and presents a true immunoassay.
Conclusions: Many solid phases have specific reactive groups which can be activated by a variety of biochemical methods.  This research shows that 
we can manufacture the cost-effective IRMA kits by producing locally the antibody-coated tubes for PSA.  And they can be used in mass screening of 
the prostate cancer for men over 50 in any country.  Finally the same protocol for coating monoclonal antibodies can be used for other tumor markers 
like CEA, CA15-3 and AFP if we have their specific monoclonal antibodies.
Key words: solid phase, coated tubes, immunoassay, prostate-specific antigen.
Serum, when it contains specific antibodies, is referred to as 
antiserum.  All the antibodies have the same basic structure 
of 4 polypeptide chains: two identical “light” chains and two 
identical “heavy” chains linked together by disulfide bonds in 
a distinctive Y conformation. Immunoglobulins are divided 
into classes (IgG, IgM, IgE, IgA and IgD) and subclasses (IgG1, 
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IgG2, etc).  IgG class immunoglobulins constitute about 75% 
of total serum immunoglobulins. The antibodies that are 
produced by hyper-immunization are predominantly IgG, 
occasionally with IgM. And IgM antibodies are often less 
stable [2, 8].
The initial stimulation of antibody production is usually 
achieved in an animal after the injection of immunogen. 
The administration of immunogen stimulates different cells 
of the immune system, giving rise to a mixed population of 
antibodies derived from a number of B-lymphocyte clones 
(polyclonal).  The serum taken from an immunized animal 
containing these antibodies is referred to as a polyclonal 
antiserum [3, 5].
In the recent years, the usage of monoclonal antibody 
(mcAb) in the immunoassay has rapidly been established 
along with involving a variety of approaches.  Kohler and 
Milstein’s original method was to fuse B-cells antibodies with 
neoplastic tumor cells (B-cell myeloma), producing immortal 
hybrid cells.
There are three factors necessary for judicious selection 
of antibodies:
1. Concentration of binding sites
2. Affinity
3. Specificity
It is, therefore, important to detail or indicate the aspects 
of the above in order to characterize all antibodies if they are 
to be used as immune reagents.  The most practical tests are:
1. Determination of titer.  This is a measure of both con-
centration and affinity.
2. Scatchard’s analysis of binding curve.  This gives the 
details of both affinity and number of binding sites.
3. Cross-reaction studies with structurally related mol-
ecules.  This can give the the information to describe the type 
and degree of specificity.
In this research we have used the pairs of monoclonal Ab 
from a commercial company.  One of them has been used 
before for making the tracer with 125I and the other one has 
been used for coating on a solid phase.  In solid phase assays, 
the antibody is physically adsorbed on or chemically coupled 
to a solid phase.  The reaction takes place between the antigen 
molecules on the liquid phase and the antibody on the solid 
phase, and hence these assays are called solid phase assays. 
Several solid phase systems are available and a widely used 
one is a coated tubes system [7, 11].
This system uses antibody-coated polystyrene plastic tubes 
into which the buffer, a standard or unknown one, and the 
tracer are added.  After the incubation the contents of the 
tubes are discarded and the tube is rinsed to remove the last 
traces of the un-reacted reagents.  The tube is then checked 
for radioactivity.
Material and methods
First we prepare a coating buffer.  For this purpose we 
weigh 0.31 g of NaH2PO4, 2H20 and 1.2 g of Na2HpO4, 2H2O, 
also 0.5 g of NaN3.  Then we dissolve it in the distilled water 
and make one liter volume.  After that we prepare the anti-PSA 
monoclonal antibody coating solution.  The concentration 
of master monoclonal antibodies (mAb) is 7.5 mg/ml, and 
for making the coating solution we have to dilute it by one 
thousand times, that is up to 7.5 µg/ml.  For obtaining this 
concentration we add 100 µl of the master mAb solution to 
100 ml of the coating buffer.  We mix it well gently and dis-
pense 0.4 ml of this homogenous solution to each polystyrene 
tube, incubate the tubes overnight at the room temperature. 
Then we make a post-coating buffer as follows: 6.0 g. of Tris 
reagent, 3.2 g of Citric acid, 10 g of Sodium citrate, 1.0 g of 
NaN3 (sodium azide), 10 g of BSA and 10 g of Sucrose, then 
we dissolve it in the distilled water and bring the volume to 
one liter.
The next day, we at first aspirate the antibody solution 
from the tubes then we dispense 0.5 ml of post-coating buffer 
to each tube and incubate it overnight.
During the coating process most of the antibody mol-
ecules are tightly fixed to the solid phase surface.  But some 
of them, which are the low fixed antibody molecules, have to 
be removed during the post-coating treatment in order not 
to interfere with the future antigen-antibody reaction [9, 10]. 
At the same time, the final coated antibody molecules have 
to be protected during their conservation.  For this purpose 
some protecting ingredients have already been added to the 
post-coating buffer as well.  After the coating process the 
tubes must be dried in an appropriate room and the drying 
process lasts overnight.  The coated tubes could also be kept 
in a humid form for a short term (for a few weeks).  In this 
case, the coated tube could be kept with the post-coating buf-
fer containing the amount of 0.1% NaN3, at 4-8°C.  The dried 
coated tubes are meant for a long-term conservation (from 
several months to years).  For this purpose the dried coated 
tubes have to be packed in an appropriate box with desiccants.
We should also make the iodinated PSA-antibody (tracer) 
to perform the immunoradiometric assay (IRMA) with locally 
made anti-PSA coated tubes in order to evaluate the efficiency 
of our coated tubes.  For this we use the other pair of anti-PSA 
monoclonal antibodies for iodination with radioisotope (125I).
The best way for iodination of proteins or antibodies is 
the Chloramine-T method [1, 12].  First we take 100 µg (10 
µl) of master monoclonal antibodies and pour them into a 
small plastic tube, then we add 10 µl (0.5 m Ci) of the iodine 
(125I) solution and 10 µl (5 µg in phosphate buffer, pH = 7.4) 
of Chlorrmine-T which is an oxidizing agent and causes the 
conversion of negative iodine into positive iodine in order to 
bind the protein molecule.  After 30 seconds we add 10 µl (5 
µg in phosphate buffer, pH = 7.4) of Sodium meta bisulfite as 
a reducing agent to quench the reaction.
Then we purify the labeled mixture by using Sephadex 
G-25 column.  Finally we dilute the labeled anti-PSA antibody 
(tracer) by phosphate buffer and adjust the activity of the 
tracer by measuring it in the gamma-counter to use it in the 
laboratory for doing the assay.
The assay protocol is as follows: 
Patient sample serum and control serum standard is 
added sequentially to antibody-coated tubes 100 µl.  100 µl 
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of anti-PSA labeled antibody (tracer) is added to each tube 
and the tubes are mixed by Vortex mixer.  Then the tubes are 
incubated at a room temperature for two hours while shaking.
At the end the contents of the tubes are aspirated care-
fully, the tubes are twice rinsed with 2 ml of wash buffer and 
aspirated immediately.  Finally, the tubes are counted in the 
gamma-counter and the standard curve is made.
Results and discussion
After running the assay the results show a good and ac-
ceptable standard curve.  The amount of PSA in the control 
serum and patient samples are compatible with the samples 
checked by Beckman’s commercial kit (tab. 1, 2).
Table 1
The concentration of the standards and their counts
Standards Concentration (ng/ml)
Counts per minute 
(cpm)
st. 1 0 360
st. 2 1 1264
st. 3 3 4962
st. 4 10 17321
st. 5 30 38678
st. 6 100 59864
Table 2
The comparison of the results between two different 
coated tubes
Patient Samples
Local kit
PSA (ng/ml)
Commercial kit
PSA (ng/ml)
1 4.6 4.7
2 2.2 2.1
3 5.9 5.8
4 1.9 2.0
5 3.6 3.5
6 7.5 7.6
7 8.3 8.2
8 12.4 12.2
9 9.6 9.7
10 4.2 4.1
As we see in fig. 1, the standard curve shows a good 
proportion between the radioactivity counts of the standard 
samples and their concentrations which is a typical IRMA 
curve.
The normal value of PSA concentration in healthy men 
is 0-4 ng/ml, but it is recommended that each laboratory 
should establish its own norm values for the local healthy 
population regarding the age and other potential ethnic and 
regional differences.  When the sample value is higher than 
the concentration of the highest standard value, we should 
dilute it by a zero standard value.  The mentioned thing usually 
happens to the samples of patients with developed prostate 
carcinoma accomplished by bone metastasis.  In this situation 
the obtained results must be multiplied by the dilution factor.
After comparing the results of two different coated tubes 
we can easily come to the fact that there is a good correlation 
between the amounts of the PSA in samples measured by our 
local coated tubes and those which are made by means of the 
commercial kit (fig. 2).
Concentration
Fig. 1.  The standard curve of PSA-IRMA using locally made anti-
PSA monoclonal Ab coated tubes.
Fig. 2.  The correlation curve between the two results.
Comercial kit
LLLocally made kit
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Conclusions
Immunoassays are the most widely used analytical tech-
niques and have been successfully applied to an extensive 
range of substances, including those with large and small 
molecules.  Many solid phases have specific reactive groups 
which can be activated by a variety of biochemical methods. 
After introducing Yalow and Berson’s isotopic method for 
measuring insulin in the clinical laboratories it has been 
spread very quickly to many analytes including the tumor 
markers.  This research shows that we can manufacture the 
cost effective IRMA kit by producing antibody-coated tubes 
for PSA locally.  It can also be used for the mass screening of 
prostate cancer in men over 50 in any country, including the 
developing countries thanks to the simple procedure and its 
reasonable cost. Finally, the same protocol for coating mono-
clonal antibodies on a solid phase can be used for the other 
tumor markers like CEA, CA15-3 and AFP if we have their 
specific monoclonal antibodies.
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Введение
Острый варикотромбофлебит (ОВТФ) нижних конеч-
ностей часто считают безопасным и доброкачественным 
заболеванием, которое не является причиной летальных 
исходов [1].  На самом деле, летальные случаи при ОВТФ 
далеко не редкость, и обуславливаются они, главным 
образом, тромбоэмболией лёгочной артерии (ТЭЛА).  В 
недавнем систематическом обзоре обнаружено, что при 
ОВТФ бессимптомная ТЭЛА регистрируется у 20-33% 
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Abstract
Background: The purpose of the study is the improvement of treatment results in the patients with superficial vein thrombosis, associated with 
varicose veins (SVT-AVV) of lower limbs, through studying the frequency of pulmonary embolism (PE) cases and the factors predisposing to it.
Material and methods: 236 patients with SVT-AVV have been examined and the disease has been observed in 250 lower limbs.  A triplex scanning 
of the venous system of both lower limbs with the registration of all embolic areas of superficial and deep veins has been carried out in every patient. PE 
clinic picture has been confirmed by computer angiopulmonography.
Results: The results of the study have showed that SVT-AVV is complicated by clinically distinct PE in 3.8% of cases (95% CI 1.8-7.1).  The frequency 
of PE among the persons with SVT-AVV without a thrombotic process in deep venous system has amounted to 1.1% and when this process was present – 
to 14.6% (р < 0,001).  PE has been registered more frequently in the patients with the thrombotic process in both lower limbs (p = 0.004).  In the patients 
with SVT-AVV the frequency of PE has been significantly increasing along with the increase of the number of its possible sources (p = 0.007).  The 
frequency of PE at SVT-AVV presence with the top clots localization in the small saphenous vein has not differed significantly from the same indicator 
of the great saphenous vein, indicating to the frequent underestimation of the role of this vein.
Conclusions: The survey of the patients with SVT-AVV should be directed to the thorough identification of all possible sources of PE, considering 
a special risk of its development in the persons with thrombotic process in both lower limbs and concomitant deep venous thrombosis.
Key words: venous thrombosis, varicose veins, pulmonary embolism.
Тромбоэмболия лёгочной артерии при остром варикотромбофлебите  
нижних конечностей
пациентов, а клинически выраженная – у 2-13% [2].  Ис-
следование по оценке факторов риска развития венозного 
тромбоэмболизма (MEGA) обнаружило, что клинически 
выраженный ОВТФ связан с 3,9-кратным возрастанием 
риска ТЭЛА [3].  И даже при полноценной диагностике 
и стационарном лечении больных нередко встречаются 
смертельные исходы [4, 5].
Исходя из этого, важным при лечении ОВТФ является 
вопрос выявления той категории больных, у которых есть 
